The licensed technology leverages one of BioTime’s HyStem hydrogels for localized delivery of growth factors such as brain-derived neurotrophic factor to improve recovery from stroke.
Several pre-clinical studies established significant improvement in post-stroke motor function in a murine model of ischemic stroke with the localized delivery of growth factors.
BioTime has also signed a sponsored research agreement with UCLA to support an on-going pre-clinical work related to the technology.